# Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.

> **NCT07694700** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Beni-Suef University** · enrollment: 100 (estimated)

## Conditions studied

- MDR Bacteria

## Interventions

- **DRUG:** Colistimethate sodium for injection, meropenem
- **DRUG:** Amikacin Injection and meropenem

## Key facts

- **NCT ID:** NCT07694700
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694700, "Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*